Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Philippe Aftimos's publication output changed over time?
ScholarIQpublication output · 2018–2026
Output declined50% over the shown period — from 2 works in 2018 to 1 in 2026.
2
1
1
4
2
1
201820192020202120222026
What are the most-cited papers on Philippe Aftimos?
ScholarIQmost cited works
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo
New England Journal of Medicine. 20211,601 CitationsOPEN ACCESS
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
François‐Clément Bidard, Virginia Kaklamani, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frédéric Forget, Marie‐Ange Mouret‐Reynier, Joohyuk Sohn, Donatienne Taylor, Kathleen Harnden, Hung T. Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Sunil Babu, Simon Waters, Ines Deleu, José Á. García-Sáenz, Emilio Bria, Marina Elena Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortés, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G. Conlan, Aditya Bardia
Journal of Clinical Oncology. 2022719 CitationsOPEN ACCESS
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji, Carla M.L. van Herpen, Cristina Saura, Fiona Thistlethwaite, Simon Lord, Víctor Moreno, Iain R. Macpherson, Valentina Boni, Christian Rolfo, Elisabeth G.E. de Vries, Sylvie Rottey, Jill J.J. Geenen, Ferry A.L.M. Eskens, Marta Gil-Martín, Ellen C.M. Mommers, N.P. Koper, Philippe Aftimos
The Lancet Oncology. 2019575 CitationsOPEN ACCESS
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Yacine Barèche, David Venet, Michail Ignatiadis, Philippe Aftimos, Martine Piccart, Françoise Rothé, Christos Sotiriou
Annals of Oncology. 2018378 CitationsOPEN ACCESS
Delivering precision oncology to patients with cancer
Joaquı́n Mateo, Lotte Steuten, Philippe Aftimos, Fabrice André, D. M. Davies, Elena Garralda, Jan Geißler, Don Husereau, Iciar Martinez-Lopez, Nicola Normanno, Jorge S. Reis‐Filho, Stephen Stefani, David M. Thomas, C. Benedikt Westphalen, Emile E. Voest
Nature Medicine. 2022366 CitationsOPEN ACCESS
Related on ScholarIQ
Université Libre de Bruxelles
Institution
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Paper
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Paper
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Paper
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Paper
Delivering precision oncology to patients with cancer
Paper